Press coverage about PLx Pharma (NASDAQ:PLXP) has been trending somewhat positive recently, according to Accern Sentiment. The research group ranks the sentiment of news coverage by reviewing more than twenty million news and blog sources in real-time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. PLx Pharma earned a news impact score of 0.01 on Accern’s scale. Accern also gave media coverage about the biotechnology company an impact score of 44.5738739813032 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the stock’s share price in the near future.
A number of analysts have weighed in on PLXP shares. ValuEngine upgraded shares of PLx Pharma from a “strong sell” rating to a “sell” rating in a research note on Monday, December 4th. Zacks Investment Research upgraded shares of PLx Pharma from a “sell” rating to a “hold” rating in a research note on Thursday, October 12th.
Shares of PLx Pharma (NASDAQ:PLXP) remained flat at $$7.00 during mid-day trading on Tuesday. The company had a trading volume of 42 shares, compared to its average volume of 5,820. PLx Pharma has a 52 week low of $5.60 and a 52 week high of $13.20. The stock has a market capitalization of $61.27, a P/E ratio of -1.39 and a beta of 1.82. The company has a debt-to-equity ratio of 0.56, a current ratio of 8.99 and a quick ratio of 8.88.
TRADEMARK VIOLATION NOTICE: This piece of content was originally published by Community Financial News and is the property of of Community Financial News. If you are reading this piece of content on another website, it was illegally stolen and republished in violation of U.S. & international trademark and copyright law. The correct version of this piece of content can be accessed at https://www.com-unik.info/2018/01/09/somewhat-positive-press-coverage-somewhat-unlikely-to-impact-plx-pharma-plxp-stock-price.html.
PLx Pharma Inc, formerly Dipexium Pharmaceuticals, Inc, is a biopharmaceutical company. The Company is a late stage specialty pharmaceutical company focusing on commercializing its lead products: Aspertec 325 mg and Aspertec 81 mg (Aspertec). The Company’s products and technology includes PLxGuard delivery system, Aspertec 325 mg, PL1100/PL1200 Ibuprofen.
Receive News & Ratings for PLx Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PLx Pharma and related companies with MarketBeat.com's FREE daily email newsletter.